Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient
Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Prior to the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 axis no drug demonstrated to improve survival or quality of life in the second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Nivolumab appear to have a clear clinical benefit for R/M-HNSCC, based on improved survival, good toxicit...
Alternative Titles
Full title
Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6787422
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6787422
Other Identifiers
ISSN
1662-6575
E-ISSN
1662-6575
DOI
10.1159/000502858
